Mitochondrial DNA, distinct from the nuclear genome, resides inside the mitochondrion and is inherited maternally. Its mutations contribute not only to a diverse collection of rare genetic diseases but also have implications in cancer progression and age-related cellular decline. Historically, genome editing technologies such as CRISPR-Cas9 revolutionized nuclear DNA manipulation but fell short when applied to mitochondria owing to their impermeable double membranes and the absence of natural RNA import pathways necessary for CRISPR’s function.

The innovative approach developed by the research team circumvents these challenges by deploying a highly specialized tool known as a mitochondrial base editor. This editor, a double-stranded DNA cytosine base editor (DdCBE), enables precise conversion of cytosine to thymine within the mitochondrial genome without necessitating the formation of double-stranded breaks. This subtle yet powerful mechanism ensures minimal genomic disruption, a crucial advantage given the sensitivity of mitochondrial functions.

In rigorous laboratory experiments, the researchers first engineered liver cell organoids to harbor a mutation within their mitochondrial DNA that severely compromises cellular energy production. These patient-derived liver organoids—three-dimensional tissue cultures closely replicating physiological conditions—served as effective models to study the pathophysiology of mitochondrial diseases. Upon application of the DdCBE base editor, they successfully corrected the mutation, demonstrating restoration of mitochondrial function and energy metabolism within these cells.

Moreover, the team extended their strategy to skin cells obtained from a patient diagnosed with Gitelman-like syndrome, a rare mitochondrial disorder characterized by electrolyte imbalances and neuromuscular symptoms. By targeting and repairing a pathogenic variant within these patient-derived cells, the scientists were able to restore key physiological indicators of healthy mitochondrial function. This achievement not only underscores the therapeutic potential of mitochondrial base editors but also highlights their ability to function in diverse cell types affected by mitochondrial diseases.

An essential aspect of translating this technology into clinical settings is the development of safe and efficient delivery systems for the gene editing components. The researchers innovated by delivering the RNA message encapsulating the base editor’s instructions in the form of messenger RNA (mRNA) rather than DNA plasmids, thereby mitigating the risk of genomic integration and genotoxicity. Encapsulation within lipid nanoparticles (LNPs) further enhanced delivery efficiency and reduced cellular toxicity. LNP-mediated mRNA delivery, already lauded for its success in mRNA vaccines, offers a promising vector for targeted mitochondrial therapies.

Equally significant was the high specificity of the editing process. Comprehensive genomic analyses revealed negligible off-target effects within the nuclear genome, alleviating concerns about unintended mutagenesis in the cell’s main genetic repository. While some off-target edits were detected within mitochondrial DNA, these were minimal and can be further mitigated through ongoing optimization. The precision achieved in this study underscores the technical sophistication of mitochondrial base editing, setting a new benchmark in genomic medicine.

The promise of this technique lies not only in its immediate ability to model mitochondrial diseases in vitro but also in its potential as a direct therapeutic intervention. Historically, patients with mitochondrial disorders had limited treatment options, primarily symptomatic management or supportive care. The advent of a tool capable of directly correcting the root genetic causes within mitochondria could transform clinical approaches, possibly leading to cures rather than palliation.

Importantly, this study leveraged clinic-grade techniques and patient-derived organoids, bringing the research closer to clinical application. The use of human cells and organoid models ensures translational relevance and provides a platform for evaluating therapeutic efficacy and safety with unprecedented accuracy. The approach moves the field from theoretical genome editing strategies toward tangible medical innovations.

Despite the promise, challenges remain. Efficient delivery of base editors in vivo—especially to organs predominantly affected by mitochondrial diseases like muscle and brain tissue—requires further refinement. Immune responses, editing efficiency across diverse mitochondrial haplotypes, and long-term effects of editing in post-mitotic cells present hurdles yet to be fully surmounted. Nonetheless, the demonstrated ability to edit mitochondrial DNA with base editors is a monumental leap forward.

The researchers emphasize that their work symbolizes the dawn of a new era in mitochondrial medicine, one where gene editing technologies will finally bridge the long-standing gap presented by mitochondrial genetics. For decades, mitochondrial patients have lagged behind the CRISPR revolution, but innovations such as these offer renewed hope, moving toward therapies that correct mutations at their genetic origin rather than managing their downstream consequences.

In summary, by employing mitochondrial base editors delivered via lipid nanoparticles and mRNA, scientists have charted a course toward effective, precise, and clinically viable mitochondrial DNA editing. This advance holds promise not only for rare genetic diseases but may also have far-reaching implications in tackling mitochondrial dysfunctions implicated in aging and cancer biology. Continued research and development in this arena are poised to unlock new frontiers in precision medicine.

As the field anticipates further experimental validation and eventual clinical trials, this discovery stands as a testament to the power of innovative genetic engineering. The convergence of molecular biology, bioengineering, and clinical science is paving the way for novel interventions capable of rewriting the mitochondrial genome, reshaping the landscape of genetic disease treatment forever.

Subject of Research: Cells

Article Title: Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors

News Publication Date: June 24, 2025

Web References: https://doi.org/10.1371/journal.pbio.3003207

References: Joore IP, Shehata S, Muffels I, Castro-Alpízar J, Jiménez-Curiel E, Nagyova E, et al. (2025) Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors. PLoS Biol 23(6): e3003207.

Image Credits: Martijn Koppens (CC-BY 4.0)

Keywords: mitochondrial diseases, base editing, mitochondrial DNA, DdCBE, lipid nanoparticles, mRNA delivery, gene therapy, mitochondrial mutations, patient-derived organoids, precision medicine, mitochondrial genome editing, mitochondrial pathology.

One of the significant hurdles impeding progress in understanding and treating mitochondrial diseases lies in the phenomenon of heteroplasmy. Unlike nuclear DNA mutations that are usually uniform across cells, heteroplasmy refers to the coexistence of both normal (wild-type) and mutated mtDNA within the same cell population. The ratio of these genomes can fluctuate widely across different tissues and even among cells in the same tissue, making it exceedingly difficult to establish clear correlations between mutation load and clinical outcomes. This heterogeneity complicates the development of effective therapies, as interventions must ideally target and modify the mutant mtDNA without harming the normal mitochondrial population.

Furthermore, fundamental research into mtDNA-related pathologies has been stymied by the lack of precise and reliable models. Existing systems cannot adequately replicate the diverse spectrum of heteroplasmy levels seen in patients, and currently, no technology has allowed researchers to fine-tune the mutation load bidirectionally — that is, to both decrease and increase the proportion of mutant mtDNA within cells. This obstacle has limited the ability to dissect how different mutation loads impact disease severity and progression. Without such tools, the development of targeted treatments that could alter heteroplasmy levels remained largely theoretical.

This scientific impasse has now been addressed by a multidisciplinary research group spearheaded by Senior Assistant Professor Naoki Yahata at Fujita Health University School of Medicine in Japan. In a groundbreaking study published in the June 2025 edition of Molecular Therapy Nucleic Acids, the team unveiled an innovative approach to modulate heteroplasmy in patient-derived cells harboring the m.3243A>G mutation. They developed optimized mitochondrial DNA-targeted platinum transcription activator-like effector nucleases (mpTALENs), engineered enzymes capable of selectively recognizing and cleaving specific mtDNA sequences with remarkable precision.

The method relies on harnessing two distinct mpTALEN constructs designed to address the intricacies of heteroplasmy manipulation in opposite directions. One version targets and degrades the mutant mtDNA, thereby enriching for the wild-type genome, while the other selectively cleaves the normal mtDNA to elevate the proportion of mutant genomes. This bidirectional control not only allows researchers to generate isogenic cell lines with a spectrum of mutation loads but also preserves the pluripotency and differentiation potential of the cells, enabling comprehensive downstream studies to assess functional consequences across various tissue types.

Key technological refinements underpinning this advancement include the implementation of novel non-conventional repeat-variable di-residues within the TALEN DNA-binding domains, affording enhanced specificity towards mutated mtDNA sequences. Additionally, the incorporation of obligate heterodimeric FokI nuclease domains substantially minimized off-target cleavage events, safeguarding the integrity of non-target mitochondrial and nuclear DNA. Complementary protocols, such as uridine supplementation, were instrumental in overcoming the typical proliferative disadvantages exhibited by cells with extreme heteroplasmy levels, thereby facilitating the establishment of stable, mutation load-defined cell lines.

The implications of this research are profound. By enabling precise modulation of heteroplasmy, scientists can now dissect the pathological thresholds at which mutant mtDNA begins to drive cellular dysfunction and disease phenotypes. This capability paves the way for improved disease models that closely mimic patient scenarios, yielding insights into mitochondrial dysfunction mechanisms that were previously obscured. Furthermore, the demonstrated ability to increase mutant mtDNA loads introduces a novel paradigm for studying pathogenic mutations in controlled settings, which was unprecedented before this work.

From a therapeutic perspective, the mpTALEN platform offers a promising avenue for direct clinical intervention in mitochondrial diseases. The capacity to selectively reduce mutant mtDNA burden in affected tissues holds the potential to ameliorate symptoms or even halt disease progression in patients suffering from conditions like MELAS syndrome. While challenges remain before such therapies can be translated to bedside applications — including delivery methods, long-term safety, and efficacy in vivo — this study provides vital proof-of-concept evidence that targeted genome editing of mtDNA is feasible and effective within human cells.

Moreover, this pioneering technology is not restricted exclusively to the m.3243A>G mutation; its adaptable design suggests it could be customized to target a wide array of other pathogenic mtDNA mutations. Such versatility could revolutionize the therapeutic landscape for mitochondrial diseases broadly, many of which currently lack any effective treatment options. It also offers a powerful investigative tool for elucidating the molecular underpinnings of these disorders and identifying novel drug targets.

Throughout this research endeavor, the team demonstrated meticulous optimization and validation of mpTALEN constructs, rigorously characterizing their cleavage efficiency, specificity, and lack of cytotoxicity. Their collaborative effort incorporated expertise spanning mitochondrial biology, genome engineering, and stem cell technologies, underpinning the multidisciplinary nature required to tackle complex diseases at the genomic level. Notably, the study was supported by several prominent funding bodies, including the Takeda Science Foundation and the Japan Society for the Promotion of Science.

Dr. Naoki Yahata reflects on the significance of these findings, emphasizing, "Our study is the first to demonstrate programmable nucleases can not only reduce mutant mitochondrial DNA but also increase its proportion, providing a versatile tool for mitochondrial disease research." This dual capability marks a milestone in mitochondrial genetics and offers new hope for patients enduring these devastating illnesses.

As efforts continue, it will be crucial to translate this technology into clinically viable therapies. Future research will need to address delivery mechanisms that can safely and effectively transport mpTALENs into affected tissues within patients, evaluate their long-term impacts, and potentially integrate this approach with complementary treatments. Nonetheless, the current advances herald a new era in mitochondrial medicine, where genetic precision-editing tools can finally pave the way towards targeted, personalized treatments for mitochondrial diseases.

In conclusion, the development of mtDNA-targeted platinum TALENs represents a transformative advance in the manipulation of mitochondrial heteroplasmy. By overcoming long-standing technical obstacles, this technology equips researchers with unprecedented control over mitochondrial genetics, fostering deeper understanding and opening the door to novel therapeutics. The promise it holds for millions affected by mitochondrial disorders underscores its monumental potential and significance within the biomedical field.

Subject of Research: Cells

Article Title: Optimization of mtDNA-targeted platinum TALENs for bi-directionally modifying heteroplasmy levels in patient-derived m.3243A>G-iPSCs

News Publication Date: June 10, 2025

Web References:
https://doi.org/10.1016/j.omtn.2025.102521

References:
Title of original paper: Optimization of mtDNA-targeted platinum TALENs for bi-directionally modifying heteroplasmy levels in patient-derived m.3243A>G-iPSCs
Journal: Molecular Therapy Nucleic Acids
DOI: 10.1016/j.omtn.2025.102521

Image Credits: Credit: Dr. Naoki Yahata from Fujita Health University School of Medicine, Japan

Keywords: mitochondrial disease, mitochondrial DNA, heteroplasmy, m.3243A>G mutation, MELAS syndrome, TALEN, genome editing, pluripotent stem cells, mitochondrial therapeutics, mpTALEN, mitochondrial genetics, iPSCs

Recent groundbreaking research has uncovered the molecular mechanism by which TALEDs harness the cell’s innate DNA repair machinery to enable efficient adenosine-to-guanosine (A-to-G) editing in mitochondrial genomes. By strategically leveraging the base excision repair (BER) pathway, researchers have unlocked a new frontier in precise mitochondrial genome editing. This conceptual breakthrough elucidates how TALEDs convert their substrate DNA into a single-stranded configuration amenable to site-specific adenosine deamination, fundamentally enhancing editing efficiency and specificity.

TALEDs operate through a remarkable fusion of two enzymatic functionalities: the single-stranded DNA-specific adenosine deaminase TadA8e and the double-stranded DNA (dsDNA)-specific cytidine deaminase DddA. While TadA8e mediates the actual A-to-G conversion, the newly revealed secret lies in DddA’s ability to initiate strand-specific modifications. Upon DddA-mediated deamination of cytidine residues, uracil bases arise transiently in the mtDNA, effectively flagging sites for the BER machinery. This initiates a cascade in which the base excision repair system actively excises these uracils, unwinding and transiently converting the surrounding dsDNA into single-stranded DNA (ssDNA) at targeted loci.

In this newly single-stranded state, the DNA becomes accessible to TadA8e, which then executes the adenine-to-inosine deamination, ultimately read as guanine post-replication. This remarkable choreography between cytidine deamination, uracil excision, and single-strand exposure forms the mechanistic foundation for TALED-mediated base editing. Consequently, this study debunks prior assumptions that TALEDs directly bind and edit dsDNA, highlighting instead a critical dependence on the BER pathway for the transient creation of their substrate.

The implications of this discovery have profound practical outcomes. By substituting the native DddA with an engineered, high-activity variant named DddA6, scientists have successfully amplified the initial cytidine deamination step, generating more robust signals for base excision repair engagement. This results in increased formation of single-stranded regions and consequently enhances the overall frequency and efficiency of adenine editing by TadA8e. Complementing this strategy, the fusion of human uracil DNA glycosylase to the TadA8e domain further streamlines uracil recognition and excision, thus fine-tuning the BER activation to optimize the exposure of editing substrates.

The engineering advancements culminated in the creation of a suite of enhanced TALEDs (eTALED6s), which display superior editing kinetics and substantively elevate on-target editing rates in mitochondrial DNA. Yet, the story does not end at sheer efficiency. Advanced iterations, such as the eTALED6R variant, showcase remarkable control over editing precision by minimizing both bystander and off-target modifications in DNA and RNA pools. This balancing act is critical, as uncontrolled editing could compromise mitochondrial function or incur unintended mutagenesis, potentially exacerbating disease phenotypes rather than alleviating them.

These newly engineered TALEDs open avenues for sophisticated mitochondrial gene therapy, enabling the targeted installation or correction of pathogenic point mutations responsible for mitochondrial disorders. This therapeutic promise was demonstrated conclusively through experiments that employed eTALED6 and eTALED6R to successfully introduce a disease-related mutation into mitochondrial genomes, underscoring the potential for both modeling mitochondrial diseases and devising corrective interventions.

The mechanistic insights and protein engineering strategies developed through this work represent an elegant convergence of basic molecular biology and applied biotechnological innovation. By revealing that effective A-to-G editing requires the active recruitment of cellular base excision repair pathways, the study provides a rational framework to design next-generation mitochondrial base editors. This framework can be exploited to improve targeting accuracy, reduce off-target effects, and ultimately expand the toolkit available for mtDNA manipulation.

Furthermore, the study highlights the subtle interplay between DNA damage repair and base editing, illustrating that intentional genomic modification depends not only on catalytic activity but also on the orchestration of endogenous enzymatic environments. Understanding these interdependencies is critical when considering mitochondrial DNA, given its unique architecture, replication dynamics, and limited repair options compared to nuclear DNA.

This work also raises exciting questions about the limits and possibilities of mitochondrial genome editing. For example, could further manipulation of mitochondrial BER components or engineering of additional enzymatic partners enhance editing windows or enable other types of base conversions? Could these insights be extended to other organelles or DNA contexts that are currently refractory to precise modification? Such questions open thriving territory for future exploration.

On a broader scale, by facilitating precise manipulation of mitochondrial genomes, these advances contribute to deciphering the enigmatic role of mtDNA mutations in aging and complex metabolic diseases. Researchers can now investigate causality more accurately by introducing or correcting mutations in living cells or animal models, enabling functional studies unattainable with previous technology. This ability may shed light on mitochondrial contributions to neurodegenerative diseases, cancer metabolism, and inherited metabolic syndromes.

In conclusion, the unraveling of TALED function through a base excision repair-dependent mechanism represents a milestone in mitochondrial genome engineering. The combination of enhanced deaminase variants, fusion proteins targeting uracil excision, and precise spatiotemporal control of DNA substrate availability converges to produce highly efficient and specific mitochondrial base editors. These innovative tools are poised to propel mitochondrial genetics into a new era of precision medicine, promising novel treatments for mitochondrial disorders that have long eluded effective intervention.

This breakthrough also exemplifies the power of dissecting cellular repair pathways to refine genome editing technologies, a principle that may catalyze similar improvements across diverse genome editing platforms. As the field moves forward, the integration of repair biology and protein engineering stands as a paradigm for the development of next-generation therapeutics designed to navigate and manipulate the complexities of human genetics with unprecedented fidelity.

Subject of Research:
Mitochondrial DNA adenine base editing mediated by transcription activator-like effector-linked deaminases and the role of base excision repair.

Article Title:
Leveraging base excision repair for efficient adenine base editing of mitochondrial DNA.

Article References:
Fan, Y., Xu, W., Gao, BQ. et al. Leveraging base excision repair for efficient adenine base editing of mitochondrial DNA. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02608-w

Image Credits: AI Generated

In recent years, a range of mitochondrial base editors (BEs) emerged, including DddA-derived cytosine base editors (DdCBEs) and TALE-linked deaminases (TALEDs). Our own laboratory introduced a new type of mitochondrial base editor, abbreviated mitoBE, capable of cytosine-to-thymine (C-to-T) and adenine-to-guanine (A-to-G) conversions in the mitochondrial genome. These constructs combine a double-stranded or single-stranded DNA deaminase with a DNA nickase, harnessing the potential of transcription activator-like effectors (TALEs) that are customized to bind specific sequences in mtDNA. The original version of mitoBEs, described previously, showed minimal off-target editing, primarily because the TALE design confers strong strand specificity. Nonetheless, the fervent push for generating mouse models to replicate the precise mutations implicated in human mitochondrial disorders called for an even higher level of accuracy and efficiency, particularly when microinjecting these tools as RNA into zygotes.

The next-generation variant, termed mitoBEs v2, arose from the thorough redesign of adenine and cytosine deaminases to mitigate unwanted off-target edits. When expressed in cells, the original versions of these mitochondrial base editors were shown to cause occasional undesired edits in the mitochondrial genome and, more significantly, in transcripts, because certain cytosine and adenine deaminases can inadvertently bind and deaminate RNA. This risk becomes more pronounced when the editors are delivered in the form of mRNA, which yields higher expression levels and correspondingly higher on-target editing but also riskier interactions with off-target substrates. By strategically mutating and screening key residues within TadA, a bacterial adenine deaminase commonly used for adenine base editing, the new version of mitoABE included the substitution V28F in TadA8e-V106W, leading to substantially improved specificity and reduced RNA off-target edits. In parallel, our team explored a library of cytosine deaminases for an alternative to APOBEC1—the widely used but often promiscuous deaminase—ultimately selecting CBE6d, a TadA-derived cytosine deaminase that delivered a higher degree of efficiency and a narrower editing window.

Having validated mitoBEs v2 in cultured cells, we systematically screened 70 pathogenic point mutations in the mouse mitochondrial genome that mirror known human mutations. Among these, we found 68 to be editable by mitoBEs v2, indicating that the modified editors maintain broad applicability for disease modeling. The editing efficiency often exceeded 10%, and in some loci, including mt-Rnr1 A978G, mt-TrnV G1029A, mt-Atp6 T8576C, mt-Atp6 T8591C, mt-Nd5 T12499C, and mt-Nd5 A12784G, we observed rates of up to 20–25% in cultured neuroblastoma cells. While such cell-line testing provides only an initial screening for the feasibility of each target site, it also reveals the interplay between TALE binding, deaminase activity, and the architecture of the target sequence in shaping how effectively any given site can be mutated.

The next challenge was to translate this high efficiency to live animals, where editing has to happen at the zygote stage so that every cell in the adult mouse carries the mtDNA change, making it possible to recapitulate human disease phenotypes. We chose two specific positions for in vivo proof-of-concept studies: mt-Atp6 T8591C, corresponding to the human m.T9191C mutation implicated in Leigh syndrome, and mt-Nd5 A12784G, mirroring the human m.A13379G mutation implicated in LHON. When we delivered mRNA or circRNA encoding the new mitoBEs v2 into one-cell mouse embryos, the editing efficiencies reached unprecedented levels. Notably, circRNA-encoded mitoBEs v2 proved more effective than mRNA-encoded versions, often doubling the mutation rates. In some embryos, we attained editing efficiency upward of 60% at T8591C or 62% at A12784G when analyzed at the blastocyst stage. Extending this success to live offspring, many F0 mice carried mutation loads of 40–50% or even up to 82% at their respective loci, underscoring the ability of mitoBEs v2 to create highly heteroplasmic or near-homoplasmic conditions.

This level of editing in F0 mice is particularly important for studying mitochondrial disorders because disease phenotypes often manifest only when the proportion of mutated mtDNA surpasses a threshold. In LHON, for instance, the typical threshold is around 60% for the mutant mtDNA to induce the visual impairments commonly observed in patients, though lower loads can sometimes be sufficient. By generating mice in which the majority of their mtDNA is mutated, we produce more faithful analogs of human disease states, facilitating a clearer understanding of pathological mechanisms and the development of treatments. Importantly, we verified the specificity of these edits. Whole-genome sequencing revealed no significant off-target editing within the nuclear genome at relevant sequencing depths, and a thorough survey of potential off-target sites, including computational predictions with TALENoffer, showed the background to be effectively clean. Even in the mitochondrial genome, where the original version of mitoCBEs occasionally introduced off-target conversions, the new cytosine deaminase variant CBE6d displayed minimal detectable bystander or off-target edits.

One of the most intriguing discoveries about these newly engineered mice was the extent to which the mutations were stably propagated across various somatic tissues and over time. By sampling 26 tissues at 2 months of age in two different F0 mice, we saw that editing levels remained relatively stable in many tissues. Some variations were detected, which could be due to the interplay between environmental factors, tissue-specific energetic demands, and potential selective pressures on certain mtDNA variants. Indeed, such tissue-specific segregation is part of the broader story of the mitochondrial genetic bottleneck, wherein different subpopulations of mtDNA can get amplified or suppressed depending on energetic or developmental constraints.

The question of heritability was addressed by mating female mice carrying the edited mtDNA with wild-type males. mtDNA is well known to be maternally inherited in mammals. We observed that mutation loads fluctuated in F1 and F2 generations, sometimes increasing, sometimes decreasing, a classic manifestation of the mitochondrial bottleneck effect. Remarkably, some F1 offspring attained 100% mutation load at the A12784G site, showcasing the potential to generate fully homoplasmic lines within just one generation. In contrast, the T8591C variants seemed detrimental to embryonic development or gamete maturation, as illustrated by lower birth rates in those lines and a gradual diminution of the T8591C mutation over subsequent generations. By the F2 or F3 generation, T8591C either was substantially reduced or disappeared in most offspring, pointing to a powerful selective force that eliminates highly deleterious mtDNA variants.

These lineage-tracking observations in mice are emblematic of the broader phenomenon experienced by human carriers of pathogenic mtDNA. Some families are known to spontaneously lose or reduce detrimental variants over generations, presumably because these variants compromise oocyte or embryo viability. Conversely, other variants, even if pathogenic, can persist or expand under certain circumstances. The ability to control and quantify these effects in a laboratory mouse population is an invaluable asset for dissecting exactly how mitochondrial heteroplasmy shifts occur, what molecular signals lead to selection for or against certain mtDNA haplotypes, and how to potentially intervene in disease scenarios.

Phenotypic characterization of the F0 mice revealed disease-relevant symptoms that mirror clinical data in humans. Mice with high editing levels at T8591C in mt-Atp6 had significantly reduced heart rates and a notably diminished left ventricular ejection fraction as assessed by echocardiography. Leigh syndrome is often associated with severe cardiovascular and neurological abnormalities. The phenotypic data in these mice strengthen the link between that particular point mutation and the observed phenotype, consistent with human clinical observations that T9191C can lead to Leigh syndrome with pronounced cardiac manifestations. Similarly, the mice carrying the A12784G mutation in mt-Nd5 displayed impaired visual function evidenced by electroretinography. Under dark-adapted conditions, both a-wave and b-wave responses were suppressed in these animals, and under light-adaptation conditions, the b-wave responses were notably depressed. LHON in humans is characterized by central vision loss, optic atrophy, and deficits in the photoreceptor signals, which aligns with these findings. By recapitulating such phenotypes, these new mouse lines represent crucial platforms for future interventions, drug testing, and mechanistic analyses of mitochondrial diseases.

Despite these accomplishments, a challenge remains in achieving truly single-base alterations without introducing secondary edits in the adjacent window. Because TALE-based editors typically incorporate a small window in which deamination can occur, multiple bases within that window can be converted if the sequence context permits. While the presence of bystander mutations is tolerable in certain therapeutic contexts, disease modeling demands the highest precision to unambiguously link genotype to phenotype. In the present study, we addressed this by shifting the TALE-binding sites in the mt-Nd5 A12784G system, effectively narrowing the potential editing window so that only the base at position 12784 is selectively edited. Indeed, some screening in cell lines identified pairs of TALE monomers that yield cleaner edits, and embryo injections of these improved pairs gave rise to F0 mice whose only edit was at the target site. Phenotypic tests using electroretinography on these single-mutation mice confirmed that even in the absence of neighboring bystander mutations, the A12784G change was sufficient to cause LHON-like visual defects. Therefore, rational design of TALE binding, coupled with the improved catalytic specificity of deaminases, can yield nearly perfect single-base mitochondrial edits.

The success of mitoBEs v2 in generating robust mouse models of disease points the way to further possibilities in therapeutic development. Gene therapy approaches using adeno-associated virus or lipid-based nanoparticle systems could, in principle, deliver these editors to adult tissues. However, the inefficiency of delivering proteins or RNAs specifically to mitochondria in vivo remains a formidable obstacle. The impetus to solve such challenges is growing, given that more than 90 disease-related point mutations in human mtDNA have been identified. Of these, around 85 are theoretically addressable by some form of base editor that converts A-to-G or C-to-T. Although the present study focuses on using mitoBEs v2 to produce heritable changes in mouse zygotes, one can envision analogous methods, refined delivery vehicles, or direct in vivo injections that eventually correct pathogenic variants in patients.

Moreover, the principle of generating clean backgrounds for disease modeling fosters confidence that the observed phenotypes reflect the intended single mutation or cluster of mutations, rather than confounding off-target effects in the nuclear genome. As we scaled from single-blastocyst analyses to whole-litter screens and then entire F0 and F1 cohorts, we saw no evidence of spurious large-scale nuclear edits or integration events, which historically have bedeviled certain gene-editing tools. This is crucial not only for basic science but also for any translational endeavor where specificity is key to meeting regulatory standards for safety.

Another intriguing aspect of the new mitochondrially targeted editors is their compatibility with circular RNA (circRNA). CircRNA vectors are more stable than linear mRNAs, conferring prolonged expression. This was reflected in the heightened editing efficiencies in mouse embryos injected with circRNA constructs, where sustained editor expression presumably facilitated more comprehensive editing of mtDNA. The successful translation of circRNA in mitochondria-targeted editing underscores the broader potential of circular RNA technologies across various domains of gene therapy, from disease modeling in preclinical species to future therapeutic interventions in humans.

In sum, the research on mitoBEs v2 ushers in a new era of mitochondrial disease modeling, bridging the gap between theoretical constructs of disease-causing mutations and fully realized mouse lines that recapitulate human syndromes. The capacity to achieve editing efficiencies of up to 82% in F0 mice, combined with the successful demonstration of maternal inheritance and phenotypic manifestations closely matching known human conditions, is a definitive testament to the power of these refined genome-editing tools. These mouse models have already yielded insights into how pathogenic mtDNA influences embryonic and tissue-specific viability, how the mutation load can shift dramatically from mother to offspring, and how single-point changes in critical mitochondrial proteins directly provoke the cardinal features of Leigh syndrome or LHON. For the research community, the newly minted mouse lines that mimic other mitochondrial disorders—be it through tRNA mutations or protein-coding gene alterations—offer an expansive toolkit to elucidate unknown mechanisms and test novel therapeutic strategies.

The quest for single-base editing in mitochondrial DNA, once limited by a dearth of tools and hampered by the intricacy of delivering effectors to mitochondria, is now coming to fruition. The lessons learned from the iterative optimization of mitoBEs v2—especially the efforts to minimize RNA off-target edits and reduce promiscuous deaminase activity—will undoubtedly inform future developments, perhaps enabling the next generation of mitochondrially targeted editors to be even safer and more precise. Ultimately, the synergy between robust mitochondrial base editing and advanced in vivo delivery systems could herald genuine clinical interventions for a wide spectrum of mitochondrial disorders, enabling the possibility that familial burdens associated with debilitating mutations can be alleviated by precise reprogramming of the mitochondrial genome. Far from being a mere technical feat, these breakthroughs embody a promising leap toward conquering inherited metabolic conditions that have long stood as insurmountable clinical challenges.

Subject of Research: Mitochondrial genome base editing to create mouse models of human mitochondrial diseases

Article Title : Precise modelling of mitochondrial diseases using optimized mitoBEs

News Publication Date : 22 January 2025

Keywords : Mitochondrial diseases, base editing, mitoBEs v2, genome editing, animal models, TALE-fused deaminases, off-target effects, maternal inheritance, disease phenotypes, Leigh syndrome, LHON, circRNA technology